Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
It works as a triple hormone receptor agonist which target the following receptors: GLP-1 receptors GIP receptors Glucagon receptors This triple fuction makes retatrutide prominent from other medications such as semaglutide or tirzepatide
Hone Health - FDA Peptide Ban: Discusses FDA concerns leading to ban on compounded peptides including BPC-157
Retatrutides GLP-1 activity reduces hunger and slows gastric emptying, making large protein-rich meals difficult to tolerate
from Seeing positive changes in my PSSM/EPSM horse
8.1 Potential risks and monitoring The geographical location of natural habitats of selenium-enriched plants should be kept in mind in the differential diagnosis, including the patient dietary history
